HC Wainwright Reiterates “Buy” Rating for TuHURA Biosciences (NASDAQ:HURA)

TuHURA Biosciences (NASDAQ:HURA)‘s stock had its “buy” rating reaffirmed by research analysts at HC Wainwright in a research note issued on Friday,Benzinga reports. They currently have a $12.00 target price on the stock. HC Wainwright’s price target suggests a potential upside of 212.50% from the stock’s current price.

TuHURA Biosciences Stock Performance

NASDAQ:HURA opened at $3.84 on Friday. TuHURA Biosciences has a 1 year low of $1.80 and a 1 year high of $7.93. The business has a 50 day moving average price of $3.65.

TuHURA Biosciences (NASDAQ:HURA) last issued its quarterly earnings results on Thursday, May 15th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.02).

Institutional Investors Weigh In On TuHURA Biosciences

Institutional investors and hedge funds have recently modified their holdings of the company. Accent Capital Management LLC acquired a new stake in TuHURA Biosciences during the fourth quarter valued at $29,000. TT Capital Management LLC acquired a new stake in TuHURA Biosciences in the 4th quarter valued at about $41,000. Jefferies Financial Group Inc. acquired a new stake in shares of TuHURA Biosciences in the fourth quarter valued at approximately $54,000. Bank of America Corp DE acquired a new position in TuHURA Biosciences during the fourth quarter worth $59,000. Finally, Charles Schwab Investment Management Inc. purchased a new stake in shares of TuHURA Biosciences in the fourth quarter valued at about $61,000. Institutional investors and hedge funds own 0.62% of the company’s stock.

TuHURA Biosciences Company Profile

TuHURA Biosciences, Inc (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA’s lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.